Intentar ORO - Gratis

Heated startup race is on to capture AI-driven APAC healthcare

BioSpectrum Asia

|

BioSpectrum Asia June 2021

The Artificial Intelligence (AI) ecosystem in healthcare has grown in the recent past, as companies are looking to capitalise on the benefits provided by AI to improve patient outcomes and enable convenient, cost-effective access to healthcare solutions. In addition to the significant increase in digital penetration and internet connectivity, favourable government policies (e.g., China, Thailand and the Philippines) have been key driving factors of growth in health-tech startups across the Asia Pacific (APAC) region. AI in the APAC healthcare market is set to grow substantially due to increasing investments by Venture Capitalists in AI healthcare startups, cross-industry partnerships and collaborations.

- Apoorva Bajaj

Heated startup race is on to capture AI-driven APAC healthcare

AI is being used by health-tech startups for various applications within the healthcare domain such as Patient Data Analytics, Medical Imaging, Lifestyle Monitoring, Drug Discovery, Vaccine Trials , Virtual Assistants, Wearables, Health-records, Mental Health & Wellness, and Robot-Assisted Surgery, Dosage Error Reduction among others. Medical Imaging based on Deep Learning Neural Networks (a sub-field of AI) can be used in diagnosing diseases with the help of historical data. AI can also be used in detecting cancerous tissues and diagnosing certain chronic heart diseases.

APAC lags in VC funding

In terms of total venture capital (VC) funding received by healthcare startups across the globe, North American startups accounted for approximately 60 per cent, followed by APAC startups with approximately 25 per cent; and European & Middle East and North Africa (MENA) startups with approximately 15 per cent of the total funding. In 2020, VC funding for APAC startups had increased by around 37 per cent Year over Year (YoY).

In 2020, within the healthcare domain for APAC-based startups, the Diagnostics sub-sector received around 20 per cent of the total funding; e-Marketplace received 15 per cent; followed by Insurance Tech and Nutrition & Wellness sub-sector with 10 per cent of the total VC funding.

MÁS HISTORIAS DE BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Waters launches charge detection mass spectrometry technology

US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia

The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

WHO strengthens coordination for NTD programmes and supply chain delivery

The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

All-in-one coronavirus vaccines to save millions in future pandemics

A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

NTU in Singapore introduces Master of Science course in Chinese Medicine

From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

ProSpecBio launches Activin-A recombinant protein for brain injury research

Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

PAHO publishes guide for designing AI instructions in public health

The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Prerna launches India's first MicroRNA based blood test for breast cancer screening

Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan

Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.

time to read

1 min

BioSpectrum Asia Nov 2025

Translate

Share

-
+

Change font size